Kane Biotech Expands Canadian Wound Care Reach via OMS Distribution Deal
Event summary
- Kane Biotech signed a non-exclusive distribution agreement with Ontario Medical Supply Inc. (OMS) on September 2, 2026.
- OMS will distribute Kane’s FDA-cleared and Health Canada-approved revyve Antimicrobial Wound Gel and Spray.
- OMS is one of two authorized distributors for Ontario Health atHome, serving 680,000 patients annually.
- Wound care accounts for 40-50% of home-care nursing visits in Ontario, per published estimates.
The big picture
This deal strengthens Kane’s Canadian distribution network, leveraging OMS’s established relationships with Ontario Health atHome. The partnership targets a critical segment of the wound care market, where biofilm-related complications drive significant clinical and cost burdens. With wound care representing nearly half of home-care nursing visits, this expansion aligns with broader industry trends toward specialized antimicrobial solutions.
What we're watching
- Market Penetration
- Whether OMS can drive sustainable adoption of revyve in Ontario’s high-volume wound care segment.
- Regulatory Dynamics
- How Health Canada and FDA approvals will influence broader commercialization efforts.
- Competitive Positioning
- The pace at which Kane can secure additional distribution deals to expand its Canadian footprint.
Related topics